Article Sidebar

PDF
Date Published: 28/01/2025
Abstract Views: 10
Views PDF: 4
DOI: https://doi.org/10.56535/jmpm.v50i1.1024
Issue
Vol. 50 No. 1 (2025): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 1 - 2025
Section
Articles
How to Cite
Ha, V. Q., Nguyễn , Đ. T., Nguyễn, T. T., & Srin, V. (2025). VALUES OF PRETREATMENT RED CELL DISTRIBUTION INDEX IN PATIENTS WITH MULTIPLE MYELOMA. Journal of Military Pharmaco-medicine, 50(1), 81-91. https://doi.org/10.56535/jmpm.v50i1.1024

VALUES OF PRETREATMENT RED CELL DISTRIBUTION INDEX IN PATIENTS WITH MULTIPLE MYELOMA

Van Quang Ha1, , Đức Thuận Nguyễn 1, Thị Thu Nguyễn1, Vatha Srin2
1 Bộ môn - Trung tâm Nội Dã chiến, Bệnh viện Quân y 103, Học viện Quân y
2 Bệnh viện Quân y Trung ương 179 Campuchia

Main Article Content

Abstract

Objective: Studying on the prognostic values of RDW index in patients with Multiple Myeloma treated at Military Hospital 103. Subjects and methods: A case-control study was conducted on 65 patients diagnosed and treated for multiple myeloma at Department – ​​Field Internal Center, Military Hospital 103 from January 2014 to August 2024. Results: Compared to patients with stage I or II ISS, those with stage III ISS showed a higher RDW index. Patients in the RDW ≤14% group had a treatment response rate of 87.1%, higher than that of patients in the RDW >14% group (76.5%). After therapy, the RDW index considerably decreased in the complete response or partial response group. RDW index more than 14% increased the risk progression and death in patients with Multiple Myeloma by 2.895 times and 2.402 times, respectively. The progression-free survival (PFS=23.1 months) and overall survival (OS =32.1 months) means of patients in the RDW >14% group were statistically significantly lower compared to PFS (29.4 months) and OS (52.7 months) means of patients in the RDW ≤14%, with p values ​​of p = 0.039 and p 0.012, respectively. Conclusion: RDW is related to ISS stage and is may be an independent prognostic indicator for patients with Multiple Myeloma

Article Details

Keywords

Multiple myeloma, Red blood cell distribution width, Military Hospital 103

References

1. Greipp PR, Miguel JS, Durie BG, et al. International staging system for multiple myeloma. Journal of Clinical Oncology. 2005; 23(15):3412-3420.
2. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: A report from International Myeloma Working Group. Journal of Clinical Oncology. 2015; 33(26):2863-2869.
3. D'agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the HARMONY project. Journal of Clinical Oncology. 2022; 40(29):3406-3418.
4. González-Calle V, Slack A, Keane N, et al. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Annals of Hematology. 2018; 97:1453-1462.
5. Lee H, Kong S-Y, Sohn JY, et al. Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma. BioMed Research International. 2014; 2014(1):145619.
6. Zhou D, Xu P, Peng M, et al. Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma. Clinica Chimica Acta. 2018; 481:34-41.
7. Wang J, Xie X, Cheng F, et al. Evaluation of pretreatment red cell distribution width in patients with multiple myeloma. Cancer Biomarkers. 2017; 20(3):267-272.
8. Meng S, Ma Z, Lu C, et al. Prognostic value of elevated red blood cell distribution width in Chinese patients with multiple myeloma. Annals of Clinical & Laboratory Science. 2017; 47(3):282-290.
9. Ma Y, Jin Z, Zhou S, et al. Prognostic significance of the red blood cell distribution width that maintain at high level following completion of first line therapy in mutiple myeloma patients. Oncotarget. 2018; 9(11):10118.
10. Atanackovic D, Hildebrandt Y, Templin J, et al. Role of interleukin 16 in multiple myeloma. Journal of the National Cancer Institute. 2012; 104(13):1005-1020.